Kronos Bio Inc Company Overview
About Kronos Bio Inc
Kronos Bio (NASDAQ:KRON) is a biotechnology organization dedicated to transforming the lives of those affected by cancer. With a razor-sharp focus on developing innovative therapies that target the most elusive cancer-driving proteins, Kronos Bio is at the forefront of pioneering research. The company's work spans from early discovery to clinical development, aiming to unlock new pathways for treating cancer more effectively. Their projects often involve cutting-edge technology to understand cancer's complexities better and address unmet medical needs within oncology. As they progress, their primary objectives include pushing the boundaries of science to bring novel treatments to the market and significantly improve patient outcomes in the cancer care landscape.
Snapshot
Operations
Products and/or services of Kronos Bio Inc
- Development of small molecule therapeutics targeting dysregulated transcription in cancer, aiming for precision oncology treatments.
- Focused research on inhibitors that target the MYC oncogene, connected to various cancer types.
- Discovery and development of novel small molecules for hematologic malignancies and solid tumors, expanding treatment options.
- Advanced screening technology for identifying potential cancer drug candidates, using cutting-edge chemical biology approaches.
- Collaborations with academic and research institutions to leverage expertise in cancer biology and drug discovery.
- Investments in proprietary technologies to enhance drug discovery platforms and accelerate bringing new treatments to patients.
Kronos Bio Inc executive team
- Dr. Deborah A. Knobelman Ph.D.Interim CEO, CFO, COO & President
- Mr. Joshua A. KazamCo-Founder & Director
- Mr. David M. Tanen J.D.Secretary & Director